Abbott Labs Reports Material Agreements & New Financial Obligation

TL;DR

**Abbott Labs just reported new material agreements and financial obligations, but the filing is light on details.**

AI Summary

Abbott Laboratories filed an 8-K on January 29, 2024, indicating an "Entry into a Material Definitive Agreement," "Termination of a Material Definitive Agreement," and "Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement." While the filing confirms these events occurred on January 29, 2024, it does not provide specific details about the nature or financial impact of these agreements or obligations. This matters to investors because without specific details, it's impossible to assess the potential positive or negative financial implications for Abbott Laboratories' stock price or future performance.

Why It Matters

This filing signals significant corporate actions by Abbott Laboratories, but the lack of specific details prevents investors from understanding the potential financial impact on the company's valuation or future earnings.

Risk Assessment

Risk Level: medium — The filing indicates significant corporate actions (material agreements, new financial obligations) without providing any specific details, creating uncertainty for investors.

Analyst Insight

Investors should monitor future filings from Abbott Laboratories for specific details regarding these material agreements and financial obligations to assess their potential impact. Without further information, it's difficult to make an informed investment decision based solely on this 8-K.

Key Players & Entities

• ABBOTT LABORATORIES (company) — the registrant filing the 8-K
• January 29, 2024 (date) — date of the earliest event reported
• 100 Abbott Park Road (address) — principal executive offices of Abbott Laboratories
• 224-667-6100 (phone_number) — registrant's telephone number

Forward-Looking Statements

• Abbott Laboratories will file another 8-K or a 10-Q/K with more details about these material agreements and financial obligations. (Abbott Laboratories) — high confidence, target: Q1 2024 earnings report or subsequent filing

FAQ

From the Filing

0001104659-24-007725.txt : 20240129 0001104659-24-007725.hdr.sgml : 20240129 20240129161051 ACCESSION NUMBER: 0001104659-24-007725 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240129 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24573755 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm244188d1_8k.htm FORM 8-K false 0000001800 Common Shares, Without Par Value ABT 0000001800 2024-01-29 2024-01-29 0000001800 us-gaap:CommonStockMember exch:XCHI 2024-01-29 2024-01-29 0000001800 us-gaap:CommonStockMember exch:XNYS 2024-01-29 2024-01-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Common Shares, Without Par Value   ABT       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549       FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   January 29, 2024 Date of Report (Date of earliest event reported)     ABBOTT LABORATORIES (Exact name of registrant as specified in charter)       Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)       100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class Trading Symbol(s) Name of Each Exchange  on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨